Results 41 to 50 of about 1,973 (178)

Sevelamer carbonate experience in Indian end stage renal disease patients. [PDF]

Indian J Nephrol, 2012
This open label, multicentric, comparative clinical trial was done to compare the efficacy and tolerability of two sevelamer formulations, sevelamer carbonate, and sevelamer hydrochloride, in the treatment of hyperphosphatemia in Indian end stage renal disease (ESRD) patients. A total of 97 ESRD patients on hemodialysis, were enrolled.
Abraham G, Kher V, Saxena S, Jayakumar M, Chafekar D, Pargaonkar P, Shetty M, Reddy YN, Reddy YN.   +8 more
europepmc   +4 more sources

PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.

PLoS ONE, 2017
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated.
Atsushi Yaguchi, Satoshi Tatemichi, Hiroo Takeda, Mamoru Kobayashi   +3 more
doaj   +1 more source

Correction of hyperphosphatemia in hemodialysis patients: 12-month findings from a randomized study

Український Журнал Нефрології та Діалізу, 2022
. The aim of our study was to compare the safety and effectiveness of the use of sevelamer with calcium acetate for hyperphosphatemia control in hemodialysis patients. Materials and methods.
I.O. Dudar, O.M. Loboda, E.K. Krasyuk, S.L. Dudar   +3 more
doaj   +1 more source

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients

Kidney International Reports, 2018
In this phase III, open-label, single-arm, multi-center 12-week study, we evaluated the efficacy and safety of combination therapy with sucroferric oxyhydroxide (PA21) and calcium carbonate for hemodialysis patients with hyperphosphatemia.
Fumihiko Koiwa, Keitaro Yokoyama, Masafumi Fukagawa, Tadao Akizawa   +3 more
doaj   +1 more source

Long-Term Effects of Sevelamer on Vascular Calcification, Arterial Stiffness, and Calcification Propensity in Patients Receiving Peritoneal Dialysis: The Randomized Pilot SERENE (Sevelamer on Vascular Calcification, Arterial Stiffness) TrialPlain-Language Summary

Kidney Medicine, 2022
Rationale & Objective: There is a concern regarding increased risk of vascular calcification with the use of calcium-based phosphorus binders. This study aimed to compare the effects of sevelamer used as a second-line, low-dose therapy with calcium ...
Angela Yee-Moon Wang, MD, PhD, Andreas Pasch, MD, PhD, Chun-Kwok Wong, PhD, Ida Miu-Ting Chu, BSc, Tak-Ka Tang, MPH, Jessie Chu, BSc, Charmaine Cheuk-Ying Fong, BSc, Yat-Yin Yau, FRANZCR, FHKCR, Wai-Kei Lo, MD   +8 more
doaj   +1 more source

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 309-322, June 2026.
ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa, Daisuke Honda, Seigo Akari, Tadao Akizawa   +3 more
wiley   +1 more source

Effects of Egg White Powder Supplementation on Nutritional Status, Biochemical Profile, and Oxidative Stress Markers in Diabetic Hemodialysis Patients; A Double‐Blind Randomized Controlled Trial

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Protein‐energy wasting (PEW) and oxidative stress (OS) frequently occur as complications in patients undergoing hemodialysis (HD), especially among those diagnosed with type 2 diabetes mellitus (T2DM). Egg white powder (EWP) is a low‐phosphorus, high‐ biological value protein source that may help improve nutritional and ...
Arvin Babaei, Hamta Abdollah Niya, Soudabeh Hamedi‐Shahraki, Javid Safa, Ali Tarighat‐Esfanjani   +4 more
wiley   +1 more source

Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.

PLoS ONE, 2017
BackgroundChronic kidney disease-mineral and bone disorder (CKD-MBD), a complication of chronic kidney disease, has been linked to reduced quality and length of life. High serum phosphate levels that result from CKD-MBD require phosphate-lowering agents,
Nigar Sekercioglu, Argie Angeliki Veroniki, Lehana Thabane, Jason W Busse, Noori Akhtar-Danesh, Alfonso Iorio, Luciane Cruz Lopes, Gordon H Guyatt   +7 more
doaj   +1 more source

Vascular Calcification: Mechanisms, Models, and Therapies

iNew Medicine, Volume 2, Issue 2, June 2026.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu, Shu Yang, Ziyi Chen, Xiaoxiao Yang, Zhen Liang, Yuanli Chen   +5 more
wiley   +1 more source

Calcium Carbonate versus Sevelamer Hydrochloride as Phosphate Binders after Long-Term Disease Progression in 5/6 Nephrectomized Rats [PDF]

, 2014
Our aim was to compare the effects of calcium carbonate and sevelamer-HCl treatments on calcium-phosphate metabolism and renal function in 5/6 nephrectomized (NX) rats so that long-term disease progression preceded the treatment.
Pörsti, Ilkka, Mustonen, Jukka, Törmänen, Suvi, Tokola, Heikki, Niemelä, Onni, Ruskoaho, Heikki, Eräranta, Arttu, Riutta, Asko, Kööbi, Peeter, Honkanen, Teemu, Karavalakis, Emmanouil   +10 more
core   +1 more source